PHAR
Pharming Group·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 0
Stock Price Surged Significantly
Ample Liquidity
High Gross Profit Margin
Significant Net Income Growth
High Cash/net Profit Ratio
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PHAR
Pharming Group N.V.
A biotech company that develops protein replacement therapies and precision medicines
Pharmaceutical
11/11/1988
12/23/2020
NASDAQ Stock Exchange
404
12-31
Depository Receipts (Ordinary Shares)
Darwinweg 24, 2333 CR Leiden, The Netherlands
--
Pharming Group N.V. was established on November 11, 1988 as a private limited liability company under the laws of the Netherlands under the name GENFARM B.V.GENFARM B.V. The company is a global company that is developing new protein replacement drugs to meet the urgent need for commercial treatment of rare protein drugs. The flagship of their portfolio is their recombinant human C1 esterase inhibitor (rhC1 INH) franchise. C1INH is a naturally occurring protein that controls swelling of affected tissue by down-regulating the complement cascade. Their lead product, RUCONEST, is the first and only plasma-free rhc1in protein replacement therapy. It is approved for the treatment of acute hereditary angioedema, or HAE onset. The company commercializes Rouconest in the US, the EU and the UK through its own sales and marketing organization, and in the rest of the world through its distribution network. The company is also developing rhC1INH for subsequent indications, including preeclampsia, acute kidney injury, and they are also studying the clinical efficacy of rhC1INH in COVID 19. In addition, the company is investigating their oral precision drug leniolisib (a phosphoinositol 3 kinase δ or PI3Kδ inhibitor) for the treatment of activated PI3K-delta syndrome, or APDS, in the US and European registration support phase 2/3 studies. In addition, the company is also using its GMO manufacturing technology to develop next-generation protein replacement therapies, especially for Pompe disease, which is still in the preclinical stage.
Company Financials
EPS
PHAR has released its 2025 Q3 earnings. EPS was reported at 0.1, versus the expected 0, beating expectations. The chart below visualizes how PHAR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PHAR has released its 2025 Q3 earnings report, with revenue of 97.29M, reflecting a YoY change of 29.98%, and net profit of 7.55M, showing a YoY change of 829.98%. The Sankey diagram below clearly presents PHAR's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
